Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age (PrE0405)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03834688|
Recruitment Status : Active, not recruiting
First Posted : February 8, 2019
Last Update Posted : November 14, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Eligible untreated patients will receive single arm venetoclax, bendamustine and rituximab as induction therapy. After 6 cycles, maintenance rituximab may be administered per physician discretion.
Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with mantle cell lymphoma. Venetoclax may make the cancer cells sensitive to chemotherapy. This may help to slow down the growth of cancer or may cause cancer cells to die.
The purpose of this study is to see if venetoclax in combination with bendamustine and rituximab chemotherapy is effective in treating people who have mantle cell lymphoma and to examine the side effects, good and bad, associated with this combination.
|Condition or disease||Intervention/treatment||Phase|
|Mantle Cell Lymphoma||Drug: Venetoclax Drug: Bendamustine Drug: Rituximab||Phase 2|
Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin Lymphoma (NHL) which is considered incurable with conventional therapy. With an incidence of approximately 70,000 cases diagnosed in the United States (US) per year, the disease is rare.
This is an open-label phase II study of venetoclax in combination with bendamustine and rituximab. Patients will receive induction therapy with venetoclax, bendamustine and rituximab for six cycles (1 cycle = 28 days). There will be an interim analysis after 19 patients are enrolled to evaluate for tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells which can lead to electrolyte and kidney problems.
Tumor assessments will be performed after Cycle 3-4 and at end of induction therapy.
Mandatory pre-treatment tumor tissue sample (i.e., obtained in the course of standard biopsy or surgery) will be required for research (if sufficient tissue is available).
Mandatory bone marrow aspirate (obtained in the course of standard biopsy) and peripheral blood sample will be collected at the end of treatment for Minimal Residual Disease (MRD). MRD measures the disease remaining after treatment. Optional peripheral blood samples will also be collected for future research.
10/11/2021: Due to slower than anticipated enrollment, the study was redesigned to reflect the current historical complete response rate and with a lowered sample size for prompt primary endpoint readout.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||33 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Open-Label, Single-Arm Study, Cycle 1 Dose Escalation|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age|
|Actual Study Start Date :||January 13, 2020|
|Actual Primary Completion Date :||October 20, 2022|
|Estimated Study Completion Date :||November 2024|
Venetoclax, bendamustine and rituximab as induction therapy for 6 cycles of 28 days.
Cycle 1: Venetoclax by mouth daily. The dose will gradually increase during Cycle 1. (Day 1-7: 20 mg; Day 8-14: 50 mg; Day 15-21: 100 mg; Day 22-28: 200 mg.)
Cycles 2-6: Venetoclax 400 mg by mouth daily on Days 1-10 (1 cycle = 28 days).
Cycle 1-6: Bendamustine 90 mg/m² intravenous (IV) on Days 1 and 2 of each cycle. Bendamustine may be started at 70 mg/m² in patients over the age of 75 years with comorbid conditions or patients over the age of 80 years without comorbid conditions.
Other Name: Bendamustine hydrochloride
Cycle 1-6: Rituximab 375 mg/m² IV on Day 1 of each cycle. After 2 consecutive cycles of Rituximab IV are well tolerated, Rituximab may be given subcutaneously.
- Complete Response (CR) rate at end of induction [ Time Frame: 8 months ]CR assessed in accordance with Lymphoma Response Criteria (Cheson Criteria)
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: 8 months ]Number of participants with abnormal laboratory values and/or adverse events with particular attention to TLS related to treatment
- Overall Response Rate (ORR) [ Time Frame: 8 months ]ORR assessed in accordance with Lymphoma Response Criteria (Cheson Criteria)
- Progression-Free Survival (PFS) [ Time Frame: 57 months ]PFS assessed in accordance with Lymphoma Response Criteria (Cheson Criteria)
- Overall Survival (OS) [ Time Frame: 57 months ]OS assessed in accordance with Lymphoma Response Criteria (Cheson Criteria)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||60 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients must have histologically confirmed (biopsy-proven) diagnosis of mantle cell lymphoma (MCL), with documented cyclin D1 (BCL1) expression by immunohistochemical stains and/or t(11;14) by cytogenetics or FISH.
- Patients must have measurable or evaluable disease as defined as a lymph node measuring >1.5 cm in any dimension or splenomegaly with spleen >15 cm in craniocaudal dimension.
- Age ≥ 60 years.
- No intention to undergo consolidation with high dose chemotherapy and autologous stem cell rescue (Autologous Stem Cell Transplant) in first remission.
- ECOG performance status of 0-2.
- Ability to understand and willingness to sign Institutional Review Board (IRB)-approved informed consent.
- Willing to provide mandatory tissue samples (if sufficient tissue available), bone marrow and blood samples for research purposes.
Adequate organ function as measured by the following criteria, obtained ≤ 2 weeks prior to registration:
- Absolute Neutrophil Count (ANC) ≥ 1000/mm³
- Hemoglobin ≥ 8 g/dL
- Platelets ˃75,000/mm³
- Creatinine clearance ≥ 40 mL/min, calculated with the use of 24-hour creatinine clearance or by Cockcroft-Gault formula
- Total Bilirubin ≤ 1.5x Upper Limit of Normal (ULN) or ≤ 3x ULN for patients with documented Gilbert's syndrome
- Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) ≤ 2.5x ULN
- All females of childbearing potential (not surgically sterilized and between menarche and 1 year post menopause) must have a blood test to rule out pregnancy within 2 weeks prior to registration.
- Women must not be pregnant or breastfeeding. Females of childbearing potential who are sexually active with a non-sterilized male partner and sexually active men must agree to use 2 methods of adequate contraception (hormonal plus barrier or 2 barrier forms) prior to study entry, for the duration of study participation, and for 12 months after last dose of therapy. Method of contraception must be documented.
- Patients should not have prior chemotherapy, radiotherapy or immunotherapy for lymphoma.
Patients must have no recent (<1 year) history of malignancy except for the following:
- adequately treated non-melanoma skin cancer
- adequately treated Stage I melanoma of the skin
- in situ cervical cancer
- low grade prostate adenocarcinoma (Gleason grade ≤ 6) managed with observation and stable for 6 months.
- Patients should not have known evidence of central nervous system (CNS) lymphoma.
- Patients must not have received a prior allogeneic stem cell transplant or solid organ transplant (except for cornea) for any indication.
- Patients must have no active, uncontrolled infections.
- Patients must not have active hepatitis B or be chronic carriers of hepatitis B. This is defined as patients with hepatitis B surface antigen (HBsAg) positive. Patients with prior exposure to hepatitis B (hepatitis B core antibody (anti-HBc) positive AND HBsAg negative) are allowed with a protective level hepatitis B surface antibody AND a negative hepatitis B viral load by polymerase-chain reaction (PCR).
- Patients must not have active hepatitis C (HCV) as defined by a hepatitis C viral load detectable by PCR. Patients with a negative HCV antibody are assumed to have a negative HCV viral load. Patients with a positive HCV antibody must have a negative hepatitis C viral load by PCR. Prior treatment for an active HCV infection will be allowed as long as the hepatitis C viral load by PCR is negative.
- Patients must not have known active Human Immunodeficiency Virus (HIV). Testing not required in absence of clinical suspicion.
- Patients must not have evidence of significant, uncontrolled concomitant diseases, including psychiatric diseases, that could affect compliance with the protocol or interpretation of results or that could increase risk to the patient.
- Patients must not have conditions that preclude oral administration or absorption of medications through the GI tract, including but not limited to the inability to swallow pills or malabsorption syndromes.
- Patients must not have known allergies to both xanthine oxidase inhibitors and rasburicase.
- Patients must not require the use of warfarin. Blood thinners of other classes are permitted.
Patient may not receive the following agents within 7 days prior to the first dose of venetoclax:
- Strong and moderate CYP3A inhibitors
- Strong and moderate CYP3A inducers
- Strong and moderate P-gp inhibitors
- Patients must not have consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03834688
|United States, Illinois|
|Carle Cancer Center|
|Urbana, Illinois, United States, 61801|
|United States, Indiana|
|Indiana University Simon Cancer Center|
|Indianapolis, Indiana, United States, 46202|
|United States, Michigan|
|St. Joseph Mercy Hospital Cancer Care Center|
|Ann Arbor, Michigan, United States, 48106|
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|United States, Missouri|
|Washington University School of Medicine Siteman Cancer Center|
|Saint Louis, Missouri, United States, 63110|
|United States, New Jersey|
|Rutgers Cancer Institute of New Jersey|
|New Brunswick, New Jersey, United States, 08903|
|United States, Pennsylvania|
|Penn State Cancer Institute|
|Hershey, Pennsylvania, United States, 17033|
|Reading Hospital/McGlinn Cancer Institute|
|West Reading, Pennsylvania, United States, 19611|
|United States, Virginia|
|University of Virginia Health System|
|Charlottesville, Virginia, United States, 22903|
|United States, Wisconsin|
|Gundersen Health System|
|La Crosse, Wisconsin, United States, 54601|
|Study Chair:||Craig Portell, MD||University of Virginia|
|Responsible Party:||PrECOG, LLC.|
|Other Study ID Numbers:||
ML40551 ( Other Identifier: Genentech )
|First Posted:||February 8, 2019 Key Record Dates|
|Last Update Posted:||November 14, 2022|
|Last Verified:||November 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Plan Description:||Data is proprietary|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Bcl-2 Family Protein Inhibitor
Neoplasms by Histologic Type
Immune System Diseases
Antineoplastic Agents, Immunological
Physiological Effects of Drugs
Antineoplastic Agents, Alkylating
Molecular Mechanisms of Pharmacological Action